Literature DB >> 7789095

Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.

B L Prosser1, G Beskid.   

Abstract

In vitro activities of fleroxacin, ciprofloxacin, ofloxacin, and lomefloxacin were evaluated against 25,129 fresh bacterial isolates from 51 US hospital or medical center laboratories, beginning in October of 1990. Susceptibility rates were > or = 85% against most species of Gram-negative bacteria. Notable exceptions were Pseudomonas, Acinetobacter, Xanthomonas, and Providencia. The study drugs displayed similar activity against most Gram-negative species. At least 90% of oxacillin-susceptible staphylococci were susceptible but, of oxacillin-resistant strains, only approximately 60% of Staphylococcus epidermidis and 25% of Staphylococcus aureus were susceptible to the quinolones tested. Staphylococcus saprophyticus strains were less susceptible to fleroxacin (42%) than to the other compounds (79%-97%). Ofloxacin and ciprofloxacin were more active against streptococci, and none of the compounds demonstrated appreciable activity against enterococci. Thus, the spectra of activity of fluoroquinolones illustrate that they remain effective agents for the treatment of many types of infections caused by Gram-negative pathogens.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7789095     DOI: 10.1016/0732-8893(94)00087-d

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  10 in total

Review 1.  Ofloxacin otic solution: a review of its use in the management of ear infections.

Authors:  K L Simpson; A Markham
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

Review 2.  Fluoroquinolones: place in ocular therapy.

Authors:  A Smith; P M Pennefather; S B Kaye; C A Hart
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Fluoroquinolones in paediatrics.

Authors:  D Gendrel; F Moulin
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

5.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

Review 6.  Potential new fluoroquinolone treatments for suspected bacterial keratitis.

Authors:  Rose Herbert; Mary Caddick; Tobi Somerville; Keri McLean; Shakeel Herwitker; Timothy Neal; Gabriela Czanner; Stephen Tuft; Stephen B Kaye
Journal:  BMJ Open Ophthalmol       Date:  2022-07

Review 7.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

8.  In vitro activity of fleroxacin against multiresistant gram-negative bacilli isolated from patients with nosocomial infections.

Authors:  M Araque; E Velazco
Journal:  Intensive Care Med       Date:  1998-08       Impact factor: 17.440

Review 9.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

10.  Susceptibility rates of pseudomonas aeruginosa strains to quinolones.

Authors:  Luna Adhikari; K Roy; Dechen C Tsering; Ranabir Pal; Sumit Kar
Journal:  J Lab Physicians       Date:  2010-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.